Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas

Mucosa-associated lymphoid tissue(MALT)lymphoma is an indolent extranodal marginal zone B-cell lymphoma,originating in acquired MALT that is induced in mucosal barriers as part of a normal adaptive immune response to a chronic immunoinflammatory stimulus,most notably chronic infection by Helicobacte...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 3; pp. 684 - 698
Main Authors Pereira, Marta-Isabel, Medeiros, José Augusto
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 21.01.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Mucosa-associated lymphoid tissue(MALT)lymphoma is an indolent extranodal marginal zone B-cell lymphoma,originating in acquired MALT that is induced in mucosal barriers as part of a normal adaptive immune response to a chronic immunoinflammatory stimulus,most notably chronic infection by Helicobacter pylori(H.pylori).This antigenic stimulation initially leads to lymphoid hyperplasia;the acquisition of additional genetic aberrations culminates in the activation of intracellular survival pathways,with disease progression due to proliferation and resistance to apoptosis,and the emergence of a malignant clone.There are descriptions of MALT lymphomas affecting practically every organ and system,with a marked geographic variability partially attributable to the epidemiology of the underlying risk factors;nevertheless,the digestive system(and predominantly the stomach)is the most frequently involved location,reflecting the gastrointestinal tract’s unique characteristics of contact with foreign antigens,high mucosal permeability,large extension and intrinsic lymphoid system.While early-stage gastric MALT lymphoma can frequently regress after the therapeutic reversal of the chronic immune stimulus through antibiotic eradication of H.pylori infection,the presence of immortalizing genetic abnormalities,of advanced disease or of eradication-refractoriness requires a more aggressive approach which is,presently,not consensual.The fact that MALT lymphomas are rare neoplasms,with a worldwide incidence of 1-1.5 cases per105population,per year,limits the ease of accrual of representative series of patients for robust clinical trials that could sustain informed evidence-based therapeutic decisions to optimize the quality of patient care.
AbstractList Mucosa-associated lymphoid tissue(MALT)lymphoma is an indolent extranodal marginal zone B-cell lymphoma,originating in acquired MALT that is induced in mucosal barriers as part of a normal adaptive immune response to a chronic immunoinflammatory stimulus,most notably chronic infection by Helicobacter pylori(H.pylori).This antigenic stimulation initially leads to lymphoid hyperplasia;the acquisition of additional genetic aberrations culminates in the activation of intracellular survival pathways,with disease progression due to proliferation and resistance to apoptosis,and the emergence of a malignant clone.There are descriptions of MALT lymphomas affecting practically every organ and system,with a marked geographic variability partially attributable to the epidemiology of the underlying risk factors;nevertheless,the digestive system(and predominantly the stomach)is the most frequently involved location,reflecting the gastrointestinal tract’s unique characteristics of contact with foreign antigens,high mucosal permeability,large extension and intrinsic lymphoid system.While early-stage gastric MALT lymphoma can frequently regress after the therapeutic reversal of the chronic immune stimulus through antibiotic eradication of H.pylori infection,the presence of immortalizing genetic abnormalities,of advanced disease or of eradication-refractoriness requires a more aggressive approach which is,presently,not consensual.The fact that MALT lymphomas are rare neoplasms,with a worldwide incidence of 1-1.5 cases per105population,per year,limits the ease of accrual of representative series of patients for robust clinical trials that could sustain informed evidence-based therapeutic decisions to optimize the quality of patient care.
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent extranodal marginal zone B-cell lymphoma, originating in acquired MALT that is induced in mucosal barriers as part of a normal adaptive immune response to a chronic immunoinflammatory stimulus, most notably chronic infection by Helicobacter pylori ( H. pylori ). This antigenic stimulation initially leads to lymphoid hyperplasia; the acquisition of additional genetic aberrations culminates in the activation of intracellular survival pathways, with disease progression due to proliferation and resistance to apoptosis, and the emergence of a malignant clone. There are descriptions of MALT lymphomas affecting practically every organ and system, with a marked geographic variability partially attributable to the epidemiology of the underlying risk factors; nevertheless, the digestive system (and predominantly the stomach) is the most frequently involved location, reflecting the gastrointestinal tract’s unique characteristics of contact with foreign antigens, high mucosal permeability, large extension and intrinsic lymphoid system. While early-stage gastric MALT lymphoma can frequently regress after the therapeutic reversal of the chronic immune stimulus through antibiotic eradication of H. pylori infection, the presence of immortalizing genetic abnormalities, of advanced disease or of eradication-refractoriness requires a more aggressive approach which is, presently, not consensual. The fact that MALT lymphomas are rare neoplasms, with a worldwide incidence of 1-1.5 cases per 10 5 population, per year, limits the ease of accrual of representative series of patients for robust clinical trials that could sustain informed evidence-based therapeutic decisions to optimize the quality of patient care.
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent extranodal marginal zone B-cell lymphoma, originating in acquired MALT that is induced in mucosal barriers as part of a normal adaptive immune response to a chronic immunoinflammatory stimulus, most notably chronic infection by Helicobacter pylori (H. pylori). This antigenic stimulation initially leads to lymphoid hyperplasia; the acquisition of additional genetic aberrations culminates in the activation of intracellular survival pathways, with disease progression due to proliferation and resistance to apoptosis, and the emergence of a malignant clone. There are descriptions of MALT lymphomas affecting practically every organ and system, with a marked geographic variability partially attributable to the epidemiology of the underlying risk factors; nevertheless, the digestive system (and predominantly the stomach) is the most frequently involved location, reflecting the gastrointestinal tract's unique characteristics of contact with foreign antigens, high mucosal permeability, large extension and intrinsic lymphoid system. While early-stage gastric MALT lymphoma can frequently regress after the therapeutic reversal of the chronic immune stimulus through antibiotic eradication of H. pylori infection, the presence of immortalizing genetic abnormalities, of advanced disease or of eradication-refractoriness requires a more aggressive approach which is, presently, not consensual. The fact that MALT lymphomas are rare neoplasms, with a worldwide incidence of 1-1.5 cases per 10⁵ population, per year, limits the ease of accrual of representative series of patients for robust clinical trials that could sustain informed evidence-based therapeutic decisions to optimize the quality of patient care.
Author Marta-Isabel Pereira José Augusto Medeiros
AuthorAffiliation Clinical Hematology Department Coimbra University Hospital Center Institute of Physiology,Faculty of Medicine,University of Coimbra,Azinhaga de Santa Comba
Author_xml – sequence: 1
  givenname: Marta-Isabel
  surname: Pereira
  fullname: Pereira, Marta-Isabel
  organization: Marta-Isabel Pereira, Clinical Hematology Department, Coimbra University Hospital Center, 3000-075 Coimbra, Portugal
– sequence: 2
  givenname: José Augusto
  surname: Medeiros
  fullname: Medeiros, José Augusto
  organization: Marta-Isabel Pereira, Clinical Hematology Department, Coimbra University Hospital Center, 3000-075 Coimbra, Portugal
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24574742$$D View this record in MEDLINE/PubMed
BookMark eNpVkUFr3DAQhUVISDZprz0WH3uxK2lGkXQplNA2gUAgtGchaWWvgm1tJDth_329ZLO0OowY5ps3w7xLcjqmMRDyidEGJKqvr09d88JpE6G5VnhCVpwzXXOF9JSsGKWy1sDlBbks5YlSDiD4ObngKCRK5Cvy-Jj6UKW2ug199MlZP4VcbXd9yrGKY9XZMuXoq2H2qdjalpJ8tFNYV_1u2G5SXFdTLGUOh3yw5QM5a21fwsfDf0X-_Pzx--a2vn_4dXfz_b72oHGqW03pOgDqVjjFgTKtnBSSMvB4Ta2gQduWKsdQgVcCRQDtnESwTjghAa7Itzfd7eyGsPZhnLLtzTbHweadSTaa_ytj3JguvRjQnKFUi8CXg0BOz3Mokxli8aHv7RjSXAwTDJEL4Hu0eUN9TqXk0B7HMGr2RpjFCLMYYSKYxYil4fO_yx3x98svABwUN2nsnuPYHRlN1f5pQVGhFhzVsohaooS_5uuXZA
CitedBy_id crossref_primary_10_1111_hel_12684
crossref_primary_10_1016_j_rgmxen_2018_07_002
crossref_primary_10_1186_s40792_019_0696_4
crossref_primary_10_1097_PAI_0000000000000839
crossref_primary_10_1007_s12282_020_01064_5
crossref_primary_10_34172_mejdd_2023_314
crossref_primary_10_1016_j_imu_2024_101468
crossref_primary_10_2169_internalmedicine_0487_17
crossref_primary_10_1155_2019_3819893
crossref_primary_10_1055_a_1652_1162
crossref_primary_10_1371_journal_pone_0160175
crossref_primary_10_1148_rg_2021200168
crossref_primary_10_1111_iju_14229
crossref_primary_10_7704_kjhugr_2023_0026
crossref_primary_10_1016_j_jprot_2015_05_011
crossref_primary_10_1089_fpd_2018_2495
crossref_primary_10_1016_j_bbcan_2018_04_007
crossref_primary_10_1097_MD_0000000000037117
crossref_primary_10_1128_IAI_01299_15
crossref_primary_10_3389_fimmu_2022_794251
crossref_primary_10_1371_journal_pone_0143316
crossref_primary_10_1097_MD_0000000000013528
crossref_primary_10_1016_j_jneuroim_2018_06_017
crossref_primary_10_1155_2020_7927054
crossref_primary_10_3389_fcimb_2024_1339750
crossref_primary_10_3390_ijms21082697
crossref_primary_10_1111_cen3_12401
crossref_primary_10_1136_bmjgast_2021_000685
crossref_primary_10_1007_s10689_016_9911_7
crossref_primary_10_1016_j_critrevonc_2021_103289
crossref_primary_10_1186_s40792_020_01081_8
crossref_primary_10_22416_1382_4376_2021_31_3_60_67
crossref_primary_10_1007_s10096_018_3414_4
crossref_primary_10_1093_ajcp_aqv011
crossref_primary_10_3390_antibiotics12081260
crossref_primary_10_3390_ijms22147372
crossref_primary_10_1155_2018_7410801
crossref_primary_10_1136_bcr_2018_224795
crossref_primary_10_1016_j_rgmx_2018_05_003
crossref_primary_10_23736_S0026_4806_20_07184_0
crossref_primary_10_3390_toxins9040132
crossref_primary_10_1136_bmjopen_2018_027356
crossref_primary_10_1016_j_arabjc_2021_103254
crossref_primary_10_3390_jmp5030021
crossref_primary_10_2478_rrlm_2019_0003
crossref_primary_10_3390_diagnostics11122231
crossref_primary_10_1038_s41598_022_09579_x
crossref_primary_10_3103_S0891416817010074
crossref_primary_10_3389_fcimb_2017_00185
crossref_primary_10_3389_fimmu_2018_01952
crossref_primary_10_5582_ddt_2019_01008
crossref_primary_10_1016_j_cld_2017_03_006
crossref_primary_10_1155_2017_8394593
crossref_primary_10_1016_j_oraloncology_2023_106648
crossref_primary_10_3389_fmed_2022_884188
crossref_primary_10_1007_s12029_020_00569_8
crossref_primary_10_3103_S0891416817020069
crossref_primary_10_1017_S0950268817002023
crossref_primary_10_1016_j_micpath_2018_09_005
ContentType Journal Article
Copyright 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014
Copyright_xml – notice: 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014
DBID 2RA
92L
CQIGP
W91
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.3748/wjg.v20.i3.684
DatabaseName 中文科技期刊数据库
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas
EISSN 2219-2840
EndPage 698
ExternalDocumentID 10_3748_wjg_v20_i3_684
24574742
90888889504849524851484857
Genre Journal Article
Review
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c394t-f900de349f5b8230198b757013c460a50e9af08b1483c8545e39bb743ab5b5733
IEDL.DBID RPM
ISSN 1007-9327
IngestDate Tue Sep 17 21:10:28 EDT 2024
Thu Apr 11 16:15:28 EDT 2024
Fri Aug 23 00:27:33 EDT 2024
Thu May 23 23:19:46 EDT 2024
Wed Feb 14 10:28:36 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 3
Keywords Eradication therapy
Gastric lymphoma
Mucosa-associated lymphoid tissue lymphoma
Helicobacter pylori
Nuclear factor-kappa B pathway
Marginal zone lymphoma
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c394t-f900de349f5b8230198b757013c460a50e9af08b1483c8545e39bb743ab5b5733
Notes Marta-Isabel Pereira;José Augusto Medeiros;Clinical Hematology Department Coimbra University Hospital Center;Institute of Physiology,Faculty of Medicine,University of Coimbra,Azinhaga de Santa Comba
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Telephone: +351-919-502495 Fax: +351-239-855051
Correspondence to: José Augusto Medeiros, MD, PhD, Institute of Physiology, Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. jmedeiros@fmed.uc.pt
Author contributions: Pereira MI and Medeiros JA contributed equally to this work.
PMID 24574742
PQID 1514425328
PQPubID 23479
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3921478
proquest_miscellaneous_1514425328
crossref_primary_10_3748_wjg_v20_i3_684
pubmed_primary_24574742
chongqing_primary_90888889504849524851484857
PublicationCentury 2000
PublicationDate 2014-01-21
PublicationDateYYYYMMDD 2014-01-21
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-21
  day: 21
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2014
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 19414190 - Leuk Res. 2010 Feb;34(2):184-9
15694184 - Best Pract Res Clin Haematol. 2005 Mar;18(1):57-68
21922208 - Ann Hematol. 2012 Apr;91(4):543-51
20505273 - J Clin Exp Hematop. 2010;50(1):27-38
21196657 - Saudi J Gastroenterol. 2011 Jan-Feb;17(1):69-71
20492338 - J Gastroenterol Hepatol. 2010 Apr;25(4):804-9
19036078 - Br J Haematol. 2009 Feb;144(3):367-75
17986622 - Ann Oncol. 2008 May;19(5):835-46
21055028 - Zhonghua Bing Li Xue Za Zhi. 2010 Aug;39(8):513-7
21300924 - J Clin Oncol. 2011 Mar 20;29(9):1198-203
20379095 - Nihon Shokakibyo Gakkai Zasshi. 2010 Apr;107(4):612-9
20934114 - Biomed Environ Sci. 2010 Aug;23(4):273-8
22558482 - Int J Clin Exp Pathol. 2012;5(3):260-3
20830719 - Int J Cancer. 2011 Jul 1;129(1):70-7
21207091 - Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):555-9
23043300 - Br J Haematol. 2013 Jan;160(1):47-52
16123224 - Blood. 2005 Dec 15;106(13):4210-6
21273489 - Science. 2011 Jan 28;331(6016):468-72
20954370 - Nihon Kokyuki Gakkai Zasshi. 2010 Sep;48(9):677-82
8141877 - N Engl J Med. 1993 Sep 30;329(14):987-94
21313878 - Pak J Biol Sci. 2010 Nov 1;13(21):1057-61
20206106 - Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):27-34
23076291 - Tohoku J Exp Med. 2012;228(3):223-7
20501524 - Lupus. 2010 Sep;19(10):1243-5
23417758 - Ann Hematol. 2013 Jun;92(6):807-15
16766585 - Ann Oncol. 2006 Nov;17(11):1722-3
17634408 - Blood. 2007 Nov 1;110(9):3112-21
21215096 - Zhonghua Bing Li Xue Za Zhi. 2010 Dec;39(12):814-8
21317175 - Gut. 2011 Jun;60(6):747-58
20621192 - Methods. 2010 Dec;52(4):352-8
20829382 - Blood. 2010 Sep 9;116(10):1818-9; author reply 1819-20
17639089 - Gut. 2007 Dec;56(12):1685-7
22750463 - Gastroenterology. 2012 Oct;143(4):936-42; quiz e13-4
21443666 - J Gastroenterol Hepatol. 2011 Jul;26(7):1133-8
21660567 - Tumour Biol. 2011 Oct;32(5):913-20
20651169 - AJR Am J Roentgenol. 2010 Aug;195(2):W105-17
20371958 - Intern Med. 2010;49(7):677-82
15703784 - Leukemia. 2005 Apr;19(4):652-8
20810546 - Ann Oncol. 2011 Mar;22(3):689-95
21419026 - J Coll Physicians Surg Pak. 2011 Mar;21(3):171-2
21465313 - Cancer Chemother Pharmacol. 2011 Dec;68(6):1387-95
12560219 - Blood. 2003 Jun 1;101(11):4539-46
2809679 - J Clin Oncol. 1989 Nov;7(11):1630-6
20627443 - Presse Med. 2010 Jul-Aug;39(7-8):815-22
20332482 - Anticancer Res. 2010 Feb;30(2):635-9
12740354 - Gut. 2003 Jun;52(6):912-3
20180989 - Cases J. 2010 Jan 21;3(1):33
18416467 - World J Gastroenterol. 2008 Apr 21;14(15):2388-93
17607663 - Hematol Oncol. 2007 Dec;25(4):184-8
21241410 - Helicobacter. 2011 Feb;16(1):36-41
20370339 - Ocul Immunol Inflamm. 2010 Apr;18(2):110-2
12374879 - N Engl J Med. 2002 Oct 10;347(15):1175-86
20479924 - Gut Liver. 2010 Mar;4(1):117-21
23425945 - Ann Oncol. 2013 Apr;24(4):857-77
20431728 - Gut Liver. 2009 Jun;3(2):81-7
20168055 - Korean J Gastroenterol. 2010 Feb;55(2):94-9
23295789 - J Clin Oncol. 2013 Feb 10;31(5):565-72
23281682 - Radiat Oncol. 2013;8:2
22736411 - Cancer. 2013 Jan 1;119(1):99-106
21440165 - Ann Thorac Surg. 2011 Apr;91(4):1281-3
19336742 - Haematologica. 2009 May;94(5):738-42
16647129 - Ophthalmology. 2006 Jul;113(7):1209-13
9588895 - Am J Pathol. 1998 May;152(5):1271-9
6424928 - Cancer. 1984 Jun 1;53(11):2515-24
20428202 - Leukemia. 2010 Jun;24(6):1186-96
20831770 - Cancer Sci. 2010 Nov;101(11):2443-7
1568573 - Gastroenterology. 1992 May;102(5):1628-38
21480289 - J Clin Ultrasound. 2011 May;39(4):228-32
19421710 - Invest New Drugs. 2010 Apr;28(2):171-7
21239866 - Korean J Lab Med. 2011 Jan;31(1):18-21
12406890 - Blood. 2003 Mar 15;101(6):2335-9
23284739 - PLoS One. 2012;7(12):e51681
20387709 - Pathologica. 2009 Dec;101(6):230-4
20440857 - World J Gastroenterol. 2010 May 7;16(17):2158-62
8683376 - J Pathol. 1996 Feb;178(2):122-7
21848361 - Leuk Lymphoma. 2011 Dec;52(12):2262-9
20948264 - Gan To Kagaku Ryoho. 2010 Oct;37(10):1961-4
20349062 - Pathologe. 2010 May;31(3):188-94
8075046 - Ann Oncol. 1994 May;5(5):397-400
5121694 - Cancer Res. 1971 Nov;31(11):1860-1
19965661 - Blood. 2010 Jan 21;115(3):581-91
19150940 - Ann Oncol. 2009 Apr;20(4):709-14
17659705 - World J Gastroenterol. 2007 Jul 14;13(26):3554-66
1682595 - Lancet. 1991 Nov 9;338(8776):1175-6
15837810 - J Exp Med. 2005 Apr 18;201(8):1229-41
21466771 - Dan Med Bull. 2011 Apr;58(4):C4271
6193858 - Cancer. 1983 Oct 15;52(8):1410-6
21890816 - Gut. 2012 Apr;61(4):507-13
20480837 - Int Surg. 2010 Jan-Mar;95(1):27-32
17122510 - Am J Surg Pathol. 2006 Dec;30(12):1546-53
10648389 - Blood. 2000 Feb 1;95(3):802-6
21656457 - Endoscopy. 2011 Aug;43(8):731-3
22395483 - Virchows Arch. 2012 Apr;460(4):371-7
10907943 - Ann Oncol. 2000 May;11(5):521-6
12499431 - J Clin Pathol. 2003 Jan;56(1):36-42
21460242 - Blood. 2011 Jun 9;117(23):6227-36
21261681 - Histopathology. 2011 Jan;58(1):26-38
20206110 - Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):71-7
22403257 - Blood. 2012 May 24;119(21):4838-44; quiz 5057
16367902 - Cancer Sci. 2005 Dec;96(12):835-43
19672998 - Cancer. 2009 Nov 15;115(22):5210-7
22363141 - World J Gastroenterol. 2012 Feb 21;18(7):685-91
21318155 - Patholog Res Int. 2011 Jan 24;2011:193149
21133720 - Leuk Lymphoma. 2011 Jan;52(1):42-5
20617132 - J Biomed Biotechnol. 2010;2010:104918
20625656 - Arq Bras Endocrinol Metabol. 2010 Jun;54(4):425-8
18949449 - Int J Hematol. 2008 Dec;88(5):516-23
21375161 - J Pak Med Assoc. 2011 Feb;61(2):138-41
22767556 - BMJ Case Rep. 2010;2010. pii: bcr0120102649. doi: 10.1136/bcr.01.2010.2649
17156403 - Br J Haematol. 2007 Feb;136(4):521-38
21342336 - Pediatr Int. 2011 Feb;53(1):105-7
16636337 - J Clin Oncol. 2006 Jun 1;24(16):2490-7
21425257 - Int J Cancer. 2012 Feb 15;130(4):948-58
16772602 - Blood. 2006 Oct 1;108(7):2373-83
21481576 - Respir Med. 2011 Aug;105(8):1231-7
20398194 - Pathol Int. 2010 Feb;60(2):102-6
19094584 - Zhonghua Bing Li Xue Za Zhi. 2008 Sep;37(9):604-8
20351501 - J Comput Assist Tomogr. 2010 Mar-Apr;34(2):187-92
21868762 - Clin Cancer Res. 2011 Nov 1;17(21):6623-31
20551275 - Am J Clin Pathol. 2010 Jul;134(1):112-8
15750197 - Med Oncol. 2005;22(1):57-62
19890959 - Cancer. 2010 Jan 1;116(1):106-14
22893605 - Cancer. 2013 Feb 1;119(3):629-38
20520640 - Leukemia. 2010 Aug;24(8):1487-97
21499001 - Gan To Kagaku Ryoho. 2011 Apr;38(4):663-6
23054813 - Curr Gastroenterol Rep. 2012 Dec;14(6):489-96
20440281 - Nat Rev Gastroenterol Hepatol. 2010 Jun;7(6):336-46
References_xml
SSID ssj0023352
Score 2.4123983
SecondaryResourceType review_article
Snippet Mucosa-associated lymphoid tissue(MALT)lymphoma is an indolent extranodal marginal zone B-cell lymphoma,originating in acquired MALT that is induced in mucosal...
Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent extranodal marginal zone B-cell lymphoma, originating in acquired MALT that is induced in...
SourceID pubmedcentral
proquest
crossref
pubmed
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 684
SubjectTerms Gastric Mucosa - immunology
Gastric Mucosa - microbiology
Helicobacter Infections - epidemiology
Helicobacter Infections - immunology
Helicobacter Infections - microbiology
Helicobacter Infections - therapy
Helicobacter pylori - immunology
Helicobacter pylori - pathogenicity
Humans
Immunity, Mucosal
lymphoid
lymphoma
Lymphoma, B-Cell, Marginal Zone - epidemiology
Lymphoma, B-Cell, Marginal Zone - genetics
Lymphoma, B-Cell, Marginal Zone - immunology
Lymphoma, B-Cell, Marginal Zone - microbiology
Lymphoma, B-Cell, Marginal Zone - therapy
Margina
Mucosa-associated
Prognosis
Risk Factors
Stomach Neoplasms - epidemiology
Stomach Neoplasms - genetics
Stomach Neoplasms - immunology
Stomach Neoplasms - microbiology
Stomach Neoplasms - therapy
tissue
Topic Highlight
Title Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas
URI http://lib.cqvip.com/qk/84123X/201403/90888889504849524851484857.html
https://www.ncbi.nlm.nih.gov/pubmed/24574742
https://search.proquest.com/docview/1514425328
https://pubmed.ncbi.nlm.nih.gov/PMC3921478
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fi9QwEB7u7kVfRPFXz1MiCL6YbtokTfIoh8chnMjhwb2VTDdZK7vt6u0p99876baLq2_2oVCa_iDfkPmGzHwD8KaqdAyxRN4gaq4aEzmiFNwG8g02xrK0qTj54lN1fqU-XuvrA9BTLcyQtN9gm3fLVd61X4fcyvWqmU15YrPPF6fk0wtl7OwQDslApxB9jLJSEdGwxSkMJ3JitkqNSWVl9uvbIv9ZiryVeWVTR55SaaLTqU37PVpsusV3chf7Duof1vl38uQf3ujsITwYaSR7v_3dR3AQusdwedkvA-sjI19CAOMgxMzWKSRvWduxhU9NOhq2SlnqnvsRmTBnyzsCtW_nbDPgMF6v_M0TuDr78OX0nI89E3gjndrw6ISYB6lc1Jj20Apn0WhDRK9RlfBaBOejsEhRkGws0acgHSLRCI8akzbiUzjq-i48B-Z06VA4W8SglJHkt7xEdCIUKEKciwze7SatXm-1MeqUNkWH07QyUOyVBNPoU3Q2Gbyd5nU3miKQBExNwNQETN3KmoDJ4PU07TUZe9rB8F3ob29qoieKFhlZ2gyebWHYvWvCMgOzB9BuQBLS3r9D9jUIao_2dPzfT76A-0SkUjoPL4sTONr8uA0viaxs8NVgnL8BA0Do1w
link.rule.ids 230,315,730,783,787,888,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOZQLAvEVyoeRkLjgrBPbsX1EFdUC3QpVrdSblcna26DdZGm3rfrvO84mKxZu5BApimNHfiPPG3n8hpCPRaGCDzmwCkAxWenAAARnxqNvMCHkuYmHkyfHxfhMfj9X5ztEDWdhuqT9Cuq0mS_Spr7ociuXi2o05ImNfk4O0KdnUpvRA_IQO-RyCNL7OCseI-o2OblmSE_0Wqsx6qyMbn_N0pucp7VICxNr8uRSIaGOhdr3cLlpZr_RYWy7qH9459_pk3_4o8Mn5HFPJOmX9Q8_JTu-eUZOTtq5p22g6E0QYuikmOkyBuU1rRs6K2OZjoouYp56ycoeGz-l8zuEta2ndNUh0T8vyqvn5Ozw6-nBmPVVE1glrFyxYDmfeiFtUBB30TJrQCuNVK-SBS8V97YM3ADGQaIySKC8sABIJEpQENURX5Ddpm38K0Ktyi1wa7LgpdQCPVcpACz3GXAfpjwhnzeT5pZrdQwXE6fwsgrXBoy-omQaDoV3nZBPw7xuWmMMEoFxCIxDYFwtHAKTkA_DtDs097iHUTa-vb5ySFAkLjMiNwl5uYZh09eAZUL0FkCbBlFKe_sNWlgnqd1b1Ov__vI92RufTo7c0bfjH_vkEdKqmNzD8uwN2V1dXvu3SF1W8K4z1HtwfOwt
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMAFgXiFp5GQuODEie3EPqLCqjxaVRWVerM8ib0N2k0WugXx7xlnk1UXbuQQKYpjR_5Gnm_k8TeEvC5LFXwogNUAism6CgxAcKY9-gYdQlHoeDj58Kg8OJWfztTZlVJfQ9J-DW3aLZZp154PuZWrZZ1NeWLZ8eE--vRcVjpbNSG7Tm5gp7ycAvUx1opHiYaNTl4xpCjVRq8xaq1kv77N058FT1uRljrW5SmkQlIdi7XfwiWnm39Hp7Hrpv7hnn-nUF7xSbO75M5IJum7zU_fI9d8d5-cnPQLT_tA0aMgzDDIMdNVDMxb2nZ07mKpjpouY666Y27Exzd08Ruh7duGrgc0xuelu3hATmcfvu4fsLFyAquFkWsWDOeNF9IEBXEnLTcaKlUh3atlyZ3i3rjANWAsJGqNJMoLA4BkwoGCqJD4kOx1fecfE2pUYYAbnQcvZSXQezkBYLjPgfvQ8IS83U6aXW0UMmxMnsLLKFwfMAKLsmk4FN6rhLyZ5nXbGuOQCIxFYCwCY1thEZiEvJqm3aLJx30M1_n-8sIiSZG41IhCJ-TRBoZtXxOWCal2ANo2iHLau2_QygZZ7dGqnvz3ly_JzeP3M_vl49Hnp-Q2MquY38OK_BnZW_-49M-RvazhxWCnfwDjyu1A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+Helicobacter+pylori+in+gastric+mucosa-associated+lymphoid+tissue+lymphomas&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Pereira%2C+Marta-Isabel&rft.date=2014-01-21&rft.issn=1007-9327&rft.volume=20&rft.issue=3&rft.spage=684&rft_id=info:doi/10.3748%2Fwjg.v20.i3.684&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v20_i3_684
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg